Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Net Asset Value(s)

7 Feb 2022 07:00

RNS Number : 8074A
CATCo Reinsurance Opps Fund Ltd
07 February 2022
 

FOR IMMEDIATE RELEASE

 

 

7 February 2022

CATCo Reinsurance Opportunities Fund Ltd. (the "Company")

Net Asset Value

 

 

To: SFS, London Stock Exchange and Bermuda Stock Exchange 

December 2021 Net Asset Values

Markel CATCo Investment Management Ltd., the Company's Investment Manager, announces the unaudited Net Asset Value ("NAV") of the Company's Ordinary Shares and C Shares of $0.3389 and $0.6750 respectively, as at the close of business on 31 December 2021.

 

The monthly improvement in the Ordinary and C Shares (5% and 7% respectively) is due to favourable development on the loss reserves related to the 2017 and 2018 catastrophe events, marginally offset by some additional costs associated with the Scheme of Arrangement which was announced to investors on Friday, 4 February 2022.

 

Investors are reminded that under the new terms of the Scheme of Arrangement, if the necessary approvals are obtained then the additional costs will be covered by a further contribution from Markel Corporation at the closing of the Scheme of Arrangement.

 

 

 

 

For further information:

 

Markel CATCo Investment Management Ltd.

 

Judith Wynne

General Counsel

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief of Investor Marketing

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

Numis Securities Limited

 

David Benda / Hugh Jonathan

Telephone: +44 (0) 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVUPUWPPUPPPWC
Date   Source Headline
13th Jun 20064:50 pmRNSRule 8.3- Cambridge Antibody
13th Jun 20063:54 pmRNSRule 2.10 Announcement
13th Jun 200612:18 pmRNSEPT Disclosure
13th Jun 200611:42 amRNSEPT Disclosure
13th Jun 200611:35 amRNSEPT Disclosure
13th Jun 200610:20 amRNSEPT Disclosure
12th Jun 20065:35 pmRNSRule 8.3 - Cambridge Antibody
12th Jun 200612:00 pmRNSEPT Disclosure
12th Jun 200611:34 amRNSEPT Disclosure
12th Jun 200611:14 amRNSRule 8.3- (CAT)
12th Jun 200610:08 amRNSEPT Disclosure
12th Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
9th Jun 20061:30 pmRNSRule 8.3- (CAT)
9th Jun 200612:36 pmRNSEPT Disclosure
9th Jun 200611:56 amRNSEPT Disclosure
9th Jun 200611:54 amRNSEPT Disclosure
9th Jun 200611:38 amRNSRule 8.3-Cambridge Antibody
8th Jun 20064:19 pmRNSRule 2.10 Announcement
8th Jun 20062:21 pmRNSEPT Disclosure
8th Jun 20061:14 pmRNSRule 8.3- (CAT)
8th Jun 200610:49 amRNSEPT Disclosure
7th Jun 20065:01 pmRNSHolding(s) in Company
7th Jun 20064:55 pmRNSRule 8.3- Cambridge Anti Tech
7th Jun 200612:38 pmRNSRule 8.3- (CAT)
7th Jun 200612:08 pmRNSEPT Disclosure
7th Jun 200610:00 amRNSOffer for Cambridge Antibody
6th Jun 20064:01 pmRNSRule 8.3- Cambridge Antibody
6th Jun 20063:45 pmRNSRule 8.3- Cambridge Antibody
6th Jun 200612:43 pmRNSEPT Disclosure
5th Jun 20066:00 pmRNSEPT Disclosure
5th Jun 20061:10 pmRNSRule 8.3- (CAT)
5th Jun 200612:55 pmRNSEPT Disclosure
5th Jun 200611:24 amRNSEPT Disclosure
2nd Jun 20062:14 pmRNSEPT Disclosure
2nd Jun 20061:19 pmRNSRule 8.3- (CAT)
2nd Jun 200612:27 pmRNSEPT Disclosure
2nd Jun 200612:22 pmRNSEPT Disclosure
2nd Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
1st Jun 20064:22 pmRNSRule 8.3- Cambridge Antibody
1st Jun 20063:21 pmRNSHolding(s) in Company
1st Jun 200612:25 pmRNSEPT Disclosure
1st Jun 200611:10 amRNSEPT Disclosure
31st May 20063:13 pmRNSRule 8.3- (CAT)
31st May 20063:00 pmRNSMerger Update
31st May 20061:04 pmRNSRule 8.3- Cambridge Antibody
31st May 200611:43 amRNSEPT Disclosure
31st May 200611:27 amRNSEPT Disclosure
31st May 200611:25 amRNSEPT Disclosure
30th May 20063:25 pmRNSRule 8.3- (CAT)
30th May 20063:16 pmRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.